首页> 美国卫生研究院文献>Chronic Obstructive Pulmonary Diseases: Journal of the COPD Foundation >Mortality and Exacerbations by Global Initiative for Chronic Obstructive Lung Disease Groups ABCD: 2011 Versus 2017 in the COPDGene® Cohort
【2h】

Mortality and Exacerbations by Global Initiative for Chronic Obstructive Lung Disease Groups ABCD: 2011 Versus 2017 in the COPDGene® Cohort

机译:慢性阻塞性肺疾病全球行动计划(ABCD)的死亡率和急性发作时间:COPDGene®队列中的2011年与2017年对比

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

>Background: The Global initiative for chronic Obstructive Lung Disease (GOLD) ABCD groupings were recently modified. The GOLD 2011 guidelines defined increased risk as forced expiratory volume in 1 second (FEV1) < 50% predicted or ≥ 2 outpatient or ≥ 1 hospitalized exacerbation in the prior year, whereas the GOLD 2017 guidelines use only exacerbation history. We compared mortality and exacerbation rates in the Genetic Epidemiology of COPD Study cohort (COPDGene®) by 2011 (exacerbation history/FEV1 and dyspnea) versus 2017 (exacerbations and dyspnea) classifications. >Methods: Using data from COPDGene®, we tested associations of ABCD groups with all-cause mortality (Cox models, adjusted for age, sex, race and comorbidities) and longitudinal exacerbations (zero-inflated Poisson models). >Results: In 4469 individuals (mean age 63.1 years, 44% female), individual distributions in 2011 versus 2017 systems were: A, 32.0% versus 37.0%; B, 17.6% versus 36.3%; C, 9.4% versus 4.4%; D, 41.0% versus 22.3%; (observed agreement 76% [expected 27.8%], Kappa 0.67, p<0.001). Individuals in group D-2011 had 1.1 ± 1.6 exacerbations/year (mean ± standard deviation [SD]) versus 1.4 ± 1.8 for D-2017 (median follow-up 3.7 years). Using group A as reference, for both systems, mortality (median follow-up 6.8 years) was highest in group D (D-2011, [hazard ratio] HR 5.2 [95% confidence interval (CI) 4.2, 6.4]; D-2017, HR 5.5 [4.5, 6.8]), lowest for group C (HR 1.9 [1.4, 2.6] versus HR 1.9 [1.3, 2.8]) and intermediate for group B (HR 2.6 [2.0, 3.4] versus HR 3.4 [2.8, 4.1]). GOLD 2011 had better mortality discrimination (area under the curve [AUC] 0.68) than GOLD 2017 (AUC 0.66, p<0.001 for comparison) but similar exacerbation rate prediction. >Conclusions: Relative to the GOLD 2011 consensus statement, discriminate predictive power of the 2017 ABCD classification is similar for exacerbations but lower for survival.
机译:>背景:最近修改了全球慢性阻塞性肺疾病(GOLD)ABCD分组计划。 GOLD 2011指南将增加的风险定义为上一年的强迫呼气量(FEV1)<预测的50%或≥2的门诊患者或≥1的住院加重,而GOLD 2017指南仅使用了加重病史。我们比较了COPD研究队列(COPDGene ®)的遗传流行病学(2011年(病情恶化史/ FEV1和呼吸困难))与2017年(病情恶化和呼吸困难)的死亡率和恶化率。 >方法:使用来自COPDGene ®的数据,我们测试了ABCD组与全因死亡率(根据年龄,性别,种族和合并症调整的Cox模型)和纵向病情加重的关联(零膨胀的Poisson模型)。 >结果:在4469名个人中(平均年龄63.1岁,女性占44%),2011年与2017年系统的个人分布为:A,32.0%和37.0%; B,分别为17.6%和36.3%; C,9.4%和4.4%; D,分别为41.0%和22.3%; (观察到的一致性为76%[预期为27.8%],Kappa为0.67,p <0.001)。 D-2011组的患者病情加重/年(平均±标准差[SD])为1.1±1.6,而D-2017组(中位随访时间为3.7年)为1.4±1.8。以A组为参考,对于两个系统,D组的死亡率(中位随访6.8年)最高(D-2011,[危险比] HR 5.2 [95%置信区间(CI)4.2,6.4]; D- 2017年,HR 5.5 [4.5,6.8]),C组最低(HR 1.9 [1.4,2.6]对HR 1.9 [1.3,2.8]),B组中级(HR 2.6 [2.0,3.4]对HR 3.4 [2.8) ,4.1])。 GOLD 2011的死亡率歧视(曲线下的面积[AUC] 0.68)比GOLD 2017(AUC 0.66,比较的p <0.001)更好,但预测的恶化率相似。 >结论:与2011年GOLD共识声明相比,2017 ABCD分类的预测能力在加重方面相似,但对生存率较低。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号